ArticleDiscover oncology2026
A novel ferroptosis- and endoplasmic reticulum stress-related gene signature for predicting prognosis, immune features and drug sensitivity in gastric cancer.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveWhile ferroptosis and endoplasmic reticulum stress (ERS) are implicated in gastric cancer (GC), their integrated prognostic value remains unclear. Our research aimed to construct a novel prediction model based on ferroptosis- and ERS-related genes (F&ERSRGs) to assess prognosis and identify potential therapeutic strategies for GC.
methodsWe analyzed the transcriptome and clinical data of GC cohort (n = 378) from The Cancer Genome Atlas (TCGA) database as a training set and data of three independent cohorts from the Gene Expression Omnibus (GEO) database as validation sets. Differential expression analysis for the ferroptosis- and ERS-related genes (F&ERSRGs) between tumor and normal tissues was performed. Among the differentially expressed F&ERSRGs, prognostic F&ERSRGs screened by univariate Cox regression were included in Least Absolute Shrinkage and Selection Operator (LASSO) analysis to develop a risk model. Kaplan-Meier survival analysis and receiver operating characteristic (ROC) analysis were performed to assess the performance of the model. A nomogram was developed by integrating the risk score and clinicopathological characteristics. Functional enrichment analysis and evaluation of tumor microenvironment (TME) were also conducted. In addition, drug sensitivity was predicted using data from the Genomics of Drug Sensitivity in Cancer (GDSC) database. Finally, the expression of seven signature genes was validated by quantitative real-time PCR (qRT-PCR) in clinical samples.
resultsA seven-gene (NOX4, CHAC1, MYB, SNCA, ALB, CAV1, and FABP4) predictive risk model was finally constructed. Patients were categorized as high- or low-risk using median risk score as the threshold. The area under the ROC curve (AUC) values for the 1-, 3-, and 5-year overall survival (OS) in the training cohort were 0.619, 0.680, and 0.709, respectively. Survival analysis showed a better OS in low-risk patients in the training and validation cohorts. The AUC values of the nomogram for predicting 1-, 3-, and 5-year OS were 0.709, 0.711, and 0.723, respectively. TME analyses revealed a higher M2 macrophage infiltration and an immunosuppressive TME in the high-risk group. Furthermore, High-risk patients tended to be more sensitive to sepantronium bromide.
conclusionA novel F&ERSRGs based signature was built for prognosis and treatment prediction of GC patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.